Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Shim, Byoung Shik ^a,b   Choi, Young Ki ^c   Yun, Cheol Heui ^b   Lee, Eu Gene ^a   Jeon, Yoon Seong ^a   Park, Sung Moo ^a   Cheon, In Su ^a,b   Joo, Dong Hyun ^a   Cho, Chung Hwan ^a,b   Song, Min Suk ^c   Seo, Sang Uk ^a   Byun, Young Ho ^d   Park, Hae Jung ^a   Poo, Haryoung ^e   Seong, Baik Lin ^d   Kim, Jae Ouk ^a   Nguyen, Huan Huu ^a   Stadler, Konrad ^a   Kim, Dong Wook ^f   Hong, Kee Jong ^g   Czerkinsky, Cecil ^a   Song, Man Ki ^a   more..

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

^d Yonsei University   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^f Hanyang University   (South Korea)

^g Korea National Institute of Health   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MATRIX PROTEIN; MATRIX PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG SAFETY; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; PROTEIN EXPRESSION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, SUBLINGUAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CROSS PROTECTION; FEMALE; HELA CELLS; HUMANS; IMMUNITY; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; RECOMBINANT PROTEINS; SOLUBILITY; VIRAL MATRIX PROTEINS;

EID: 82355170321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027953     Document Type: Article

References (48)

1. Steinhauer DA, Skehel JJ, (2002) Genetics of influenza viruses. Annu Rev Genet 36: 305-332.
2. Ada G, Jones P, (1986) The immune response to influenza infection. Curr Top Microbiol Immunol 128: 1-54.
3. Schotsaert M, De Filette M, Fiers W, Saelens X, (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508.
4. Holsinger L, Lamb R, (1991) Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183: 32-43.
5. Holsinger L, Nichani D, Pinto L, Lamb R, (1994) Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 68: 1551-1563.
6. Takeda M, Pekosz A, Shuck K, Pinto L, Lamb R, (2002) Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 76: 1391-1399.
7. Lamb R, Zebedee S, Richardson C, (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40: 627-633.
8. Zebedee S, Lamb R, (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
9. Ito T, Gorman O, Kawaoka Y, Bean W, Webster R, (1991) Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 65: 5491-5498.
10. Treanor J, Tierney E, Zebedee S, Lamb R, Murphy B, (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64: 1375-1377.
11. Liu W, Li H, Chen Y, (2002) N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS immunol Med Microbiol 35: 141-146.
12. Black R, Rota P, Gorodkova N, Klenk H, Kendal A, (1993) Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 74: 143-146.
13. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, et al. (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3: 102.
14. Jegerlehner A, Schmitz N, Storni T, Bachmann M, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
15. Rao S, Kong W, Wei C, Van Hoeven N, Gorres J, et al. (2010) Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret. Plos One 5: e9812.
16. Kitikoon P, Vincent AL, Janke BH, Erickson B, Strait EL, et al. (2010) Swine influenza matrix 2 (M2) protein contributes to protection against infection with different H1 swine influenza virus (SIV) isolates. Vaccine 28: 523-531.
17. Frace A, Klimov A, Rowe T, Black R, Katz J, (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17: 2237-2244.
18. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou W, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
19. Slepushkin V, Katz J, Black R, Gamble W, Rota P, et al. (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.
20. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
21. Fan J, Liang X, Horton M, Perry H, Citron M, et al. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
22. Ernst W, Kim H, Tumpey T, Jansen A, Tai W, et al. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24: 5158-5168.
23. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, et al. (2001) Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19: 3681-3691.
24. Huleatt J, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2007) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
25. Eliasson D, Bakkouri K, Schon K, Ramne A, Festjens E, et al. (2008) CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
26. Bessa J, Schmitz N, Hinton H, Schwarz K, Jegerlehner A, et al. (2008) Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38: 114-126.
27. Holmgren J, Czerkinsky C, (2005) Mucosal immunity and vaccines. Nat Med 11: S45-S53.
28. Neutra M, Kozlowski P, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
29. De Filette M, Ramne A, Birkett A, Lycke N, Lowenadler B, et al. (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-551.
30. Armstrong M, Lavelle E, Loscher C, Lynch M, Mills K, (2005) Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis 192: 1628-1633.
31. Lemiale F, Kong W, Akyurek L, Ling X, Huang Y, et al. (2003) Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77: 10078-10087.
32. Cuburu N, Kweon M, Song J, Hervouet C, Luci C, et al. (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25: 8598-8610.
33. Song J, Nguyen H, Cuburu N, Horimoto T, Ko S, et al. (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Nati Acad Sci U S A 105: 1644-1649.
34. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W, (2007) Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 4: 118.
35. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, (2004) A "universal" human influenza A vaccine. Virus Res 103: 173-176.
36. Song MS, Pascua PNQ, Lee JH, Baek YH, Lee OJ, et al. (2009) The polymerase acidic protein gene of influenza a virus contributes to pathogenicity in a mouse model. J Virol 83: 12325.
37. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, et al. (2011) Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection. J Immunol 186: 1022-1031.
38. Zhao G, Lin Y, Du L, Guan J, Sun S, et al. (2010) An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7: 9.
39. Zhao G, Du L, Xiao W, Sun S, Lin Y, et al. (2010) Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 28: 7233-7240.
40. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, et al. (2010) Versatile virus-like particle carrier for epitope based vaccines. Plos One 5: e9809.
41. Wang R, Song A, Levin J, Dennis D, Zhang N, et al. (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168-177.
42. Fu TM, Freed DC, Horton MS, Fan J, Citron MP, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385: 218-226.
43. Cox N, Subbarao K, (2000) Global epidemiology of influenza: past and present. Annu Rev of Med 51: 407-421.
44. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 361: 1-10.
45. De Jong J, Claas E, Osterhaus A, Webster R, Lim W, (1997) A pandemic warning? Nature 389: 554-554.
46. Kandun IN, Wibisono H, Sedyaningsih ER, (2006) Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 355: 2186-2194.
47. Oshitani H, Kamigaki T, Suzuki A, (2008) Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 14: 875-880.
48. Reed LJ, Muench H, (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27: 493-497.